These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 12070713)
21. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592 [TBL] [Abstract][Full Text] [Related]
22. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals. Forsberg O; Carlsson B; Malmström PU; Ullenhag G; Tötterman TH; Essand M Prostate; 2009 Jan; 69(1):70-81. PubMed ID: 18814178 [TBL] [Abstract][Full Text] [Related]
23. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan. Lin HJ; Cherng JM; Hung MS; Sayion Y; Lin JC J Biomed Sci; 2005 Dec; 12(6):925-36. PubMed ID: 16307312 [TBL] [Abstract][Full Text] [Related]
24. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595 [TBL] [Abstract][Full Text] [Related]
25. Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy. Matsueda S; Wang M; Weng J; Li Y; Yin B; Zou J; Li Q; Zhao W; Peng W; Legras X; Loo C; Wang RF; Wang HY PLoS One; 2012; 7(9):e45756. PubMed ID: 23029225 [TBL] [Abstract][Full Text] [Related]
26. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898 [TBL] [Abstract][Full Text] [Related]
27. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853 [TBL] [Abstract][Full Text] [Related]
28. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele. Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698 [TBL] [Abstract][Full Text] [Related]
29. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope. Würtzen PA; Claesson MH Int J Cancer; 2002 Jun; 99(4):568-72. PubMed ID: 11992547 [TBL] [Abstract][Full Text] [Related]
30. Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance for precursor B-ALL-specific immunotherapy. de Rijke B; Fredrix H; Zoetbrood A; Scherpen F; Witteveen H; de Witte T; van de Wiel-Van Kemenade E; Dolstra H Blood; 2003 Oct; 102(8):2885-91. PubMed ID: 12842998 [TBL] [Abstract][Full Text] [Related]
31. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. Smith HA; McNeel DG J Immunother; 2011 Oct; 34(8):569-80. PubMed ID: 21904219 [TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients. Harada M; Kobayashi K; Matsueda S; Nakagawa M; Noguchi M; Itoh K Prostate; 2003 Oct; 57(2):152-9. PubMed ID: 12949939 [TBL] [Abstract][Full Text] [Related]
33. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. Tsang KY; Zaremba S; Nieroda CA; Zhu MZ; Hamilton JM; Schlom J J Natl Cancer Inst; 1995 Jul; 87(13):982-90. PubMed ID: 7629885 [TBL] [Abstract][Full Text] [Related]
34. DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response. Guo Z; Zhang H; Rao H; Jiang D; Cong X; Feng B; Wang J; Wei L; Chen H PLoS One; 2012; 7(6):e38390. PubMed ID: 22701633 [TBL] [Abstract][Full Text] [Related]
35. [Identification of a novel HLA-A2-restrictive CTL epitope of an ovary cancer-associated antigen OVA66]. Jin S; Wang Y; Wang SJ; Zhang HZ; Li MX; Chen Y; Ge HL Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):233-6, 242. PubMed ID: 15766414 [TBL] [Abstract][Full Text] [Related]
36. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247 [TBL] [Abstract][Full Text] [Related]
37. CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Olson BM; McNeel DG Cancer Immunol Immunother; 2011 Jun; 60(6):781-92. PubMed ID: 21350948 [TBL] [Abstract][Full Text] [Related]
38. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
39. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy. Guo J; Li G; Tang J; Cao XB; Zhou QY; Fan ZJ; Zhu B; Pan XH Scand J Immunol; 2013 Sep; 78(3):248-57. PubMed ID: 23721092 [TBL] [Abstract][Full Text] [Related]